Growth Metrics

Insulet (PODD) Cost Of Revenue (2016 - 2025)

Insulet's Cost of Revenue history spans 16 years, with the latest figure at $215.2 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 29.17% year-over-year to $215.2 million; the TTM value through Dec 2025 reached $768.3 million, up 22.75%, while the annual FY2025 figure was $768.2 million, 22.74% up from the prior year.
  • Cost of Revenue reached $215.2 million in Q4 2025 per PODD's latest filing, up from $196.2 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $215.2 million in Q4 2025 to a low of $2.4 million in Q4 2021.
  • Average Cost of Revenue over 5 years is $137.6 million, with a median of $144.0 million recorded in 2023.
  • Peak YoY movement for Cost of Revenue: tumbled 96.48% in 2021, then soared 6250.0% in 2022.
  • A 5-year view of Cost of Revenue shows it stood at $2.4 million in 2021, then skyrocketed by 6250.0% to $152.4 million in 2022, then dropped by 2.49% to $148.6 million in 2023, then rose by 12.11% to $166.6 million in 2024, then grew by 29.17% to $215.2 million in 2025.
  • Per Business Quant, the three most recent readings for PODD's Cost of Revenue are $215.2 million (Q4 2025), $196.2 million (Q3 2025), and $196.9 million (Q2 2025).